[ad_1]
New York, November 28, 2021 /PRNewswire/ –
why: Global investor rights law firm Rosen Law Firm reminds buyers to pay attention to D-MARKET Elektronik Hizmetleri ve Ticaret Anonim Şirketi d/b/a Hepsiburada (NASDAQ stock code:Liver cirrhosis) Based on and/or traceable to the registration statement and prospectus related to the company (collectively referred to as the “registration statement”) July 2021 Initial public offerings (“IPO” or “sales”) of important companies December 20, 2021 Deadline for lead plaintiff.
so what: If you purchase Hepsiburada securities based on an IPO and/or traceable to the IPO, you may be entitled to compensation through contingency fee arrangements without having to pay any out-of-pocket expenses or costs.
What to do next: To join the Hepsiburada class action, please visit http://www.rosenlegal.com/cases-register-2175.html Or call Philip King, Esq. Toll free 866-767-3653 or email
The full story can be found on Benzinga.com
[ad_2]
Source link